Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe, 4 ML
Skip image gallery
Abbildung/Farbe ähnlich
Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe is a medical device indicated for the relief of pain and improvement of the function of arthritic joints and for the conservative treatment of meniscus lesions in the knee.
€339.50*
Content:
4 Milliliter
(€84.88* / 1 Milliliter)
Prices incl. VAT plus shipping costs (Kann sich je nach Land ändern)
⁴
Product number:
RA5848232
Milliliter:
Hersteller:
Product information "Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe"
Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe is a medical device indicated for the relief of pain and improvement of the function of osteoarthritic joints and for the conservative treatment of meniscus lesions in the knee.
The patented hyaluronic acid molecule in Hymovis® (HYADD®4) is a new development and cannot be compared with any other hyaluronic acid on the market:
- Hymovis® combines the good properties of low and high molecular weight hyaluronic acid without taking on their disadvantages.
- As a low molecular weight HA, it has better access to the CD44 receptor, which is responsible for synthesising the body's own HA 13
- Due to the biochemically modified molecule (HYADD4), Hymovis is more viscous and better lubricating even than cross-linked HA 6
- Despite its high viscosity in the joint, Hymovis is easy to inject like low-molecular HA
What characterises Hymovis®
Unique molecule:
- Hymovis® has a unique structure: the biochemical modification of the hyaluronic acid molecule creates a new product.
- It proves to be more resistant in stress tests compared to cross-linked HAs.1-3
Long-lasting lubrication in the joint:
- In comparison, Hymovis® achieves the better lubrication effect than cross-linked HAs and therefore also the better clinical effect.6
- Promotes hyaluronic acid synthesis: High biological activity can stimulate endogenous HA synthesis.9
Positive effect on the cartilage structure:
- Hymovis® protects intra-articular tissue and thus promotes the metabolism of the cartilage matrix.7
- Increase in cartilage volume and cartilage thickness in the lateral knee compartment due to Hymovis® was demonstrated by MRI.
- Reduced cartilage catabolism and increased collagen synthesis were demonstrated by biological markers.
High resilience:
- Reversible interactions prevent fracture of the 3D structure under high loads4,5
- Long retention time in the joint: Significantly longer stability and retention time in the joint compared to cross-linked hyaluronic acids.8
- Excellent shock absorption: The high elasticity of the molecules ensures strong pressure absorption4,5
In which cases can I use Hymovis® and what effect does it have on the patient?
Due to its molecular structure, which ensures high resilience, Hymovis® is particularly suitable for mobile, active people and competitive athletes with:
- Osteoarthritis of the knee joint (gonarthrosis) Osteoarthritis of the shoulder joint Osteoarthritis of the thumb joint (rhizarthrosis)
- Osteoarthritis of the hip joint (coxarthrosis) Osteoarthritis of the ankle joint
- Osteoarthritis in other joints Damage to the meniscus
How does Hymovis® work?
- The degenerative and inflammatory processes that occur during osteoarthritis change both the HA quantity (reduction in concentration) and the HA quality (reduction in molecular weight) in the synovial fluid and increasingly destroy the surface layer of the articular cartilage.
- In order to counteract these processes, the treatment of osteoarthritis using intra-articular viscosupplementation with exogenous hyaluronic acid was developed. Viscosupplementation with hyaluronic acid improves the mechanics of joint function, the hyaluronic acid acts as shock absorption and lubrication. It can also enable long-term effects by stimulating the body's own hyaluronic acid synthesis.
- In this way, pain can be significantly reduced and the further progression of osteoarthritis slowed.2,5,6 Hyaluronic acid can also help to reduce the need for cortisone.1
- Hymovis® differs from all other hyaluronic acid products due to its unique structure. The HA molecule has been optimised with a hydrophobic hexadecylamide side chain. In the hydrophilic environment of the joint space, the Hymovis molecules form a network, the MObile REticulum (MO.RE® technology).
- Cross-linked hyaluronic acids consist of rigid bonds between the molecules, which break when the pressure becomes too great. Modifications of the hyaluronic acid molecule in Hymovis®, on the other hand, ensure that it can repeatedly reassemble itself into a stabilising network even under high pressure due to the reversible hydrophobic interaction.4,5
- The molecule (HYADD®4) of Hymovis® therefore has a shape memory. This means that it returns to its original shape even after repeated impact or tensile movements. This results in numerous positive clinical effects for your patients, which you can find under "Features". As a result, the entire molecule remains intact for longer and can maintain its highly viscous structure. Rigid cross-links, as with all other HAs, whether linear or cross-linked, break earlier under the same pressure conditions and lose their viscous structure.
1 Benazzo F, Lovato M. OsteoArtrosi.eu 2013; 3: 8-12. 2 Zorzi Z et al. OsteoArtrosi.eu 2013; 3: 13-16. 3 Pavelka K et al. Osteoarthritis Cartilage 2010, vol. 18 n. 2 Suppl.4 Finelli I et al. Biorheology, 2011; 48 (5): 263. 5 Finelli I et al. Macromol Biosci 2009; 9: 646-653. 6 Bonnevie et al. PLoS One 2019;14(5):e0216702. 7 Henrotin Y et al. BMC Musculoskelet Disord 2019;20(1):293. 8 Data on file - enquiries to: medical(at)fidiapharma.de. 9 Information for healthcare professionals Hymovis®, status 12/2015. 10 Castagna A et al. OsteoArtrosi.eu - 2013; 3: 17-20. 11 Bannuru RR et al. Osteoarthritis and Cartilage Volume 27, Issue 11, November 2019: 1578-1589. 12 DGOOC guideline: https://www.awmf.org/leitlinien/detail/ll/033-004.html. 13 Gosh P et al. Semin Arthritis Rheum . 2002 Aug;32(1):10-37.
Dosage form
Prefilled syringe
Directions for use
- Two appointments are sufficient for your patients to use Hymovis®: Osteoarthritis: 2 injections at weekly intervals and meniscus lesions: 2 injections at 2-week intervals.
- Instructions: The application may only be carried out by qualified doctors. Please follow the instructions for use.
Ingredients
- Main ingredient: Hyadd4 (sodium hyaluronate hexadecylamide), 32mg/4ml.
- Other ingredients: Sodium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injection.
| ML: | 4 |
|---|
Mehr lesen
Warnhinweise - Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe
Anwendungshinweise
Produktempfehlungen für Sie